How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/local-anesthetic-intrathecal-block.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Local anesthetic intrathecal block — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local anesthetic intrathecal block (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Local anesthetic intrathecal block, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tetracaine Hydrochloride	TETRACAINE	Alcon Labs	Ester Local Anesthetic	Sodium channel protein type 7 subunit alpha	2005-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Alcon Labs · 1 drug in Local anesthetic intrathecal block
Bayer · 1 drug in Local anesthetic intrathecal block
Fresenius Kabi · 1 drug in Local anesthetic intrathecal block
Innocoll · 1 drug in Local anesthetic intrathecal block
Pfizer · 1 drug in Local anesthetic intrathecal block
Saint-Joseph University · 1 drug in Local anesthetic intrathecal block
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Local anesthetic intrathecal block
University of Malaya · 1 drug in Local anesthetic intrathecal block

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Local anesthetic intrathecal block:

Cite this brief

Drug Landscape (2026). Local anesthetic intrathecal block — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/local-anesthetic-intrathecal-block. Accessed 2026-06-10.

Local anesthetic intrathecal block full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing